Cymabay Therapeutics Inc., of Newark, Calif., said the proof-of-concept study of seladelpar, a peroxisome proliferator-activated receptor delta agonist, for the treatment of primary biliary cholangitis (PBC) was published by Lancet Gastroenterology and Hepatology, a peer-reviewed journal. The research was published as a collaboration involving key international PBC experts.